The message that I read loud and clear from listening to litten yesterday was that the 55% stability achieved would even be higher if the patients were line 2.
the two approved drugs that achieve 20 to 37% stability work for line 2 patients, they would be basically ineffective on line 3 & 4 I'm guessing.
imagine the results when the car t is combined with the core NK to produce the 'super killer' cell and used when patients are first diagnosed.
jen is just warming up after a cold winter, she's pumping and ready to take on Kite.
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial, page-49
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |